| Line Item | 2025-01-31 | Y/Y |
|---|---|---|
| Revenue | $1.43B | +9.3% |
| Cost of Revenue | $246.9M | +26.0% |
| Gross Profit | $1.18B | +6.3% |
| R&D Expense | $380.7M | +14.6% |
| SG&A Expense | $226.1M | -2.4% |
| Operating Income | -$162.6M | +1.3% |
| Pre-tax Income | -$78.1M | -3.0% |
| Income Tax | -$4.4M | -131.3% |
| Net Income | -$73.7M |
| Line Item | 2025-01-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $879.2M | -17.2% |
| Short-term Investments | $750.3M | -8.3% |
| Accounts Receivable | $451.1M | +3.4% |
| Current Assets | $2.34B | -9.4% |
| Total Assets | $2.87B | -3.0% |
| Current Liabilities | $798.9M | +12.3% |
| Total Liabilities | $1.02B | +8.6% |
| Line Item | 2025-01-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $320.6M | +7.2% |
| Capital Expenditures | $14.9M | +103.3% |
| Investing Cash Flow | -$45.5M | +89.6% |
| Financing Cash Flow | -$450.5M | -128.8% |
| Free Cash Flow | $305.6M | +4.8% |
| +18.0% |
| EPS (Basic) | -$0.13 | +18.8% |
| EPS (Diluted) | -$0.13 | +18.8% |
| Stockholders' Equity |
| $1.85B |
| -8.4% |